Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
324495 | Journal of the American Academy of Child & Adolescent Psychiatry | 2015 | 11 Pages |
ObjectiveImpairments associated with attention-deficit/hyperactivity disorder (ADHD) and noncompliance are prevalent in children with autism spectrum disorder (ASD). However, ADHD response to stimulants is well below rates in typically developing children, with frequent side effects. Group studies of treatments for noncompliance are rare in ASD. We examined individual and combined-effectiveness of atomoxetine (ATX) and parent training (PT) for ADHD symptoms and noncompliance.MethodIn a 3-site, 10-week, double-blind, 2 × 2 trial of ATX and PT, 128 children (ages 5–14 years) with ASD and ADHD symptoms were randomized to ATX, ATX+PT, placebo+PT, or placebo. ATX was adjusted to optimal dose (capped at 1.8 mg/kg/day) over 6 weeks and maintained for 4 additional weeks. Nine PT sessions were provided. Primary outcome measures were the parent-rated DSM ADHD symptoms on the Swanson, Nolan and Pelham (SNAP) scale and Home Situations Questionnaire (HSQ).ResultsOn the SNAP, ATX, ATX+PT and placebo+PT were each superior to placebo (effect sizes 0.57–0.98; p values of .0005, .0004, and .025, respectively). For noncompliance, ATX and ATX+PT were superior to placebo (effect sizes 0.47–0.64; p values .03 and .0028, respectively). ATX was associated with decreased appetite but was otherwise well tolerated.ConclusionBoth ATX and PT resulted in significant improvement on ADHD symptoms, whereas ATX (both alone and combined with PT) was associated with significant decreases on measures of noncompliance. ATX appears to have a better side effects profile than psychostimulants in the population with ASD.Clinical Trial Registration InformationAtomoxetine, Placebo and Parent Management Training in Autism; http://clinicaltrials.gov/; NCT00844753.